三重激动剂 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-11-18. Numbers and descriptions here follow the published literature rather than marketing material.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Studied for metabolic indications |
| Receptor activity | GIP, GLP-1, and glucagon | Single molecule, three targets |
| Development status | Investigational | Not an approved therapy |
| Common synonym | LY3437943 | Development designation |
| Administration route | Subcutaneous injection | As used in clinical studies |
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
CH3COOH + H2O ⇌ CH3COO− + H3O+ CH3COOH + NH3 ⇌ CH3COO− + NH+4 Both theories easily describe the first reaction: CH3COOH acts as an Arrhenius acid because it acts as a source of H3O+ when dissolved in water, and it acts as a Brønsted acid by donating a proton to water. In the second example CH3COOH undergoes the same transformation, in this case donating a proton to ammonia (NH3), but does not relate to the Arrhenius definition of an acid because the reaction does not produce hydronium. Nevertheless, CH3COOH is both an Arrhenius and a Brønsted–Lowry acid. Brønsted–Lowry theory can be used to describe reactions of molecular compounds in nonaqueous solution or the gas phase. Hydrogen chloride (HCl) and ammonia combine under several different conditions to form ammonium chloride, NH4Cl. In aqueous solution HCl behaves as hydrochloric acid and exists as hydronium and chloride ions. The following reactions illustrate the limitations of Arrhenius's definition:
== Election to Kerala Legislative Assembly == Anoop's father, who was the Minister for Food and Civil Supplies, died on 30 October 2011. Following this, Anoop was nominated by the Kerala Congress (Jacob) and UDF to contest from the Piravom assembly seat previously represented by his father. His father had lost the sitting seat in 2006 elections and recaptured it in 2011 election by a margin of 157 votes. Against Anoop Jacob, CPI(M)–led LDF once again fielded M. J. Jacob, who had won against T. M. Jacob in 2006 and lost in 2011. Since the result of Piravom by-election mattered heavily to the ruling UDF who had a slender margin of 1 seat in the Legislative assembly over LDF, the constituency witnessed intense campaigning from both sides. Election was held on 17 March 2012 and results were announced on 21 March 2012. Anoop Jacob won the by-election by a significant margin of 12,071 votes. He was sworn in as an MLA on 22 March 2012. Anoop took oath as the Minister for Food & Civil Supplies on 12 April 2012 and occupied office in the North Block of the Kerala Secretariat; both portfolio & office last held by his departed father.
=== Pain modulation === Like other dynorphin peptides, big dynorphin can produce analgesic effects through κ-opioid receptor (KOR) activation at spinal nociceptive sites. However, at supraspinal levels through non-opioid mechanisms involving NMDA receptor modulation and ASIC1a activation, big dynorphin can produce pro-nociceptive effects, enhancing pain sensitivity in both acute and chronic pain states.
== Research == Hong's research focuses on elucidating the structure, dynamics and mechanism of membrane proteins using ssNMR. She is particularly known for her in-depth study of the Matrix-2 (M2) proteins of influenza A viruses, which are responsible for all flu pandemics in history. M2 is an acid-activated proton channel and a membrane scission protein of the influenza virus. Hong's ssNMR studies have provided insights into the proton-conduction mechanism of this channel, by quantifying the proton transfer rates and equilibria between water and the proton-selective histidine residue. She showed that the antiviral drug amantadine inhibits proton conduction by direct occlusion of the channel pore. She determined the cholesterol-binding structure of the M2 protein, which sheds light on how cholesterol mediates M2's membrane scission function. In 2020 she determined both the influenza B M2 protein structure and the SARS-CoV-2 envelope protein structure, the latter in rapid response to COVID-19. The 1.5 Å BM2 structures in the closed and open states revealed different activation mechanisms of BM2 compared to influenza AM2. The 2.1 Å SARS-CoV-2 envelope protein structure forms the basis for antiviral drug design. Other membrane proteins that Hong's group has studied include β-hairpin antimicrobial peptides, channel-forming colicins, and viral fusion proteins. She determined the structure of the membrane toroidal pores formed by the antimicrobial peptide protegrin-1, which explained the membrane-disruptive mechanism of this peptide.
== Further reading == papuamide Ford, PW; Gustafson, KR; McKee, TC; Shigematsu, N; Maurizi, LK; Pannell, LK; Williams, DE; de Silva, ED; Lassota, P; Allen, TM; Van Soest, R; Andersen, RJ; Boyd, MR (1999). "Papuamides A-D, HIV-Inhibitory and Cytotoxic Depsipeptides from the Sponges Theonella mirabilis and Theonella swinhoei Collected in Papua New Guinea". J. Am. Chem. Soc. 121 (25): 5899–5909. Bibcode:1999JAChS.121.5899F. doi:10.1021/ja990582o. neamphamide A Oku, N; Gustafson, KR; Cartner, LK; Wilson, JA; Shigematsu, N; Hess, S; Pannell, LK; Boyd, MR; McMahon, JB (2004). "Neamphamide A. A new HIV-inhibitory depsipeptide from the Papua New Guinea marine sponge Neamphius huxleyi". J. Nat. Prod. 67 (8): 1407–11. Bibcode:2004JNAtP..67.1407O. doi:10.1021/np040003f. PMID 15332865. callipeltin A Zampella, A; D'Auria, MV; Paloma, LG; Casapullo, A; Minale, L; Debitus, C; Henin, Y (1996). "Callipeltin A, an Anti-HIV Cyclic Depsipeptide from the New Caledonian Lithistida Sponge Callipelta sp.". J. Am. Chem. Soc. 118 (26): 6202–9. Bibcode:1996JAChS.118.6202Z. doi:10.1021/ja954287p. mirabamides A-D Plaza, A; Gustchina, E; Baker, HL; Kelly, M; Bewley, CA (2007). "Mirabamides A-D. Depsipeptides from the sponge Siliquariaspongia mirabilis that inhibit HIV-1 fusion". J. Nat. Prod. 70 (11): 1753–60. Bibcode:2007JNAtP..70.1753P. doi:10.1021/np070306k. PMID 17963357.; Andjelic, CD; Planelles, V; Barrows, LR (2008). "Characterizing the Anti-HIV Activity of Papuamide A." Mar Drugs. 6 (4): 528–49. doi:10.3390/md20080027. PMC 2630844. PMID 19172193.
Sources: en.wikipedia.org
Cheating in sports McLaren Report Mitchell Report Doping at the Olympic Games Cheating at the Paralympic Games Doping in Russia Doping in China Doping in the United States Doping in East Germany BALCO scandal Caffeine use for sport Cannabis and sports Concussions in sport Doping in pigeon racing Equine drug testing Gene doping Mechanical doping Stem cell doping Technology doping
=== Translation === In 1986, convincing evidence was provided that selenocysteine (Sec) was incorporated co-translationally. Moreover, the codon partially directing its incorporation in the polypeptide chain was identified as UGA also known as the opal termination codon. Different mechanisms for overriding the termination function of this codon have been identified in prokaryotes and in eukaryotes. A particular difference between these kingdoms is that cis elements seem restricted to the neighborhood of the UAG codon in prokaryotes while in eukaryotes this restriction is not present. Instead such locations seem disfavored albeit not prohibited. In 2003, a landmark paper described the identification of all known selenoproteins in humans: 25 in total. Similar analyses have been run for other organisms. The UAG codon can translate into pyrrolysine (Pyl) in a similar manner.
Enantiomers of a chiral drug often interact in an enantioselective way in a chiral environment. This may be offered by different biotic substances (viz. proteins, nucleic acids, phospholipids and oligosaccharides). They are made up of chiral building blocks that are put together in space in handed conformations. These biological targets function as receptors for the drug enantiomers. So, at the binding sites of these receptors, enantiomers will be seen as different chemical species. The three point attachment model (Easson & Stedman model) can be used to see how chiral discrimination works. Figure depicts how the enantiomers of a drug interact with receptors in a way that depends on the drug's shape. This model was made for chiral drugs with a single stereogenic center. It says that there are three binding sites in the receptor (B', C' and D') that match the drug's pharmacophoric groups (B, C, D). A three-point fit (good fit) is possible for the eutomer at BB', CC' and DD'(Fig. A). Even though the distomer is the wrong enantiomer, it can fit either a one-point interaction (bad fit), or a two-point attachment (CC' and DD') with the same receptor site as shown in (Fig. B). Eutomer is the version that works the way you want it to, and distomer is the version that doesn't work or works in a way you don't want it to. Most of the time, the mirror-image versions have different binding affinities. In the eutomer, the ligands or moiety around a stereogenic element have more binding energy than in the distomer.
Natriuretic peptides can block the activity of the renin-angiotensin-aldosterone system (RAAS), which regulates blood pressure. Studies have shown that ANP can suppress renin secretion and aldosterone production. Additionally, natriuretic peptides suppress the sympathetic nervous system (SNS), which controls the body's "fight or flight" response. The relationship between natriuretic peptides and vasopressin, a hormone that regulates water balance, has been found through studies that have shown that ANP can suppress vasopressin signaling. Researchers are working on having a better understanding of this relationship. Animal studies show the possibility of using a vasopressin receptor antagonist along with BNP to improve heart function and blood flow.B-type natriuretic peptide (BNP) and its pro hormone NT-proBNP are especially useful in diagnosing heart failure, as their levels in the blood increase along with the severity of the condition. Rapid testing of BNP and NT-proBNP can also help distinguish between shortness of breath due to heart and lung-related causes. Monitoring NT-proBNP levels over time can provide important information about an individual's risk of developing heart failure or cardiovascular disease in the future. It can be difficult to tell if someone's having trouble breathing because of heart or lung problems. However, this can often be clarified with tests like X-rays and blood work. Rapid testing of BNP and NT-proBNP can also tell if the problem is in the heart or the lungs, though, specific lung problems can also raise NP levels.
Sources: en.wikipedia.org
It is described as a single molecule that acts at three receptors: the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This triple activity distinguishes it from agents that target one or two of these pathways.
It is characterized in the literature as an investigational agent under clinical study. Approval status depends on jurisdiction, and readers should check current regulatory information rather than assume availability.
The combination is intended to pair appetite-related and glucose-related effects with mechanisms that increase energy expenditure. Whether the combined profile offers advantages over simpler agonists is the subject of ongoing research.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。